Top Page
Proteomics International Laboratories Ltd.
(Sydney:PIQ)
Proteomics International Laboratories Ltd. (PIQ) vs. iShares MSCI Australia ETF (EWA)
Proteomics International Laboratories Ltd. Business Overview & Revenue Model
Proteomics International Laboratories Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.50M | 960.39K | 892.14K | 730.34K | 1.49M | 1.31M |
| Gross Profit | 1.46M | 960.39K | -1.12M | -1.62M | -568.62K | 497.08K |
| EBITDA | -6.74M | -10.00M | -8.40M | -7.55M | -4.56M | -2.77M |
| Net Income | -7.11M | -8.11M | -6.38M | -6.23M | -4.97M | -2.86M |
Balance Sheet | ||||||
| Total Assets | 7.02M | 14.78M | 10.88M | 10.08M | 5.40M | 8.60M |
| Cash, Cash Equivalents and Short-Term Investments | 5.33M | 11.04M | 6.64M | 6.03M | 2.11M | 5.60M |
| Total Debt | 247.67K | 277.74K | 316.39K | 64.09K | 0.00 | 69.05K |
| Total Liabilities | 1.74M | 1.81M | 1.63M | 1.75M | 2.00M | 990.19K |
| Stockholders Equity | 5.46M | 13.17M | 9.41M | 8.38M | 3.39M | 7.61M |
Cash Flow | ||||||
| Free Cash Flow | -5.51M | -6.63M | -6.00M | -6.91M | -3.67M | -2.41M |
| Operating Cash Flow | -5.46M | -6.60M | -5.59M | -5.69M | -3.54M | -2.21M |
| Investing Cash Flow | -46.19K | -29.65K | -388.02K | -1.17M | -129.46K | -191.00K |
| Financing Cash Flow | 5.87M | 11.03M | 6.59M | 10.77M | 176.10K | 5.64M |
Proteomics International Laboratories Ltd. Technical Analysis
Proteomics International Laboratories Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$44.16M | ― | -49.72% | ― | ― | 10.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$57.29M | -5.79 | -71.87% | ― | 7.65% | -19.13% | |
45 Neutral | AU$121.46M | -4.66 | ― | ― | ― | 0.66% | |
42 Neutral | AU$10.93M | ― | -469.35% | ― | ― | 46.28% | |
34 Underperform | AU$72.30M | -1.46 | -100.67% | ― | 1114.27% | 85.66% |
Proteomics International Laboratories Ltd. Corporate Events
Proteomics International Laboratories Ltd has announced its upcoming Annual General Meeting, scheduled for 21 November 2025. The company has opted for digital distribution of the Notice of Meeting, encouraging shareholders to access documents online and submit proxy votes electronically, reflecting a modern approach to shareholder engagement.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the appointment of Vicki Robinson as a new director, effective from October 14, 2025. The initial director’s interest notice indicates that Robinson currently holds no securities in the company, which suggests a neutral impact on the company’s stock ownership structure. This appointment could potentially influence the company’s strategic direction, given Robinson’s role on the board.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has expanded its collaboration with the University of Melbourne and the Royal Women’s Hospital to enhance the PromarkerEndo blood test for diagnosing endometriosis. This partnership aims to provide additional clinical validation and develop a next-generation tissue-specific test, addressing a significant global health need. The collaboration seeks to reduce the average seven-year diagnostic delay for endometriosis, potentially transforming women’s healthcare by offering a non-invasive diagnostic option. The agreement includes commercial terms granting Proteomics International an exclusive license to commercialize new intellectual property developed under the project.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the appointment of Ms. Vicki Robinson as an independent non-executive director. With over 20 years of experience in executive and governance roles, Ms. Robinson is expected to enhance the company’s strategic and decision-making capabilities. Her appointment comes at a crucial time as Proteomics International rolls out its leading diagnostic products, which have the potential to transform the management of chronic conditions such as diabetic kidney disease, endometriosis, and esophageal cancer.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the issuance of 375,000 unquoted equity securities, specifically options expiring on June 6, 2027, with an exercise price of $0.555. This issuance is part of a previously announced transaction, and these securities are not intended to be quoted on the ASX. The move reflects the company’s ongoing efforts to manage its equity and financial strategy, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced the issuance of 409,600 unquoted employee performance rights as part of an incentive scheme. These securities are restricted from transfer and will not be quoted on the ASX until the restriction period ends, indicating a strategic move to motivate and retain talent within the company.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the presentation of its PromarkerEso diagnostic test results at the World Congress for Esophageal Diseases. The test, which detects early stages of esophageal adenocarcinoma with high accuracy, is now available across Australia through telehealth consultations and physician referrals. This development could significantly improve health outcomes by enabling earlier diagnosis and treatment of esophageal cancer, a condition often diagnosed too late for effective intervention.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has achieved ISO 15189 certification for its Australian laboratory operations, marking a significant milestone in the commercialization and clinical application of its precision diagnostic tests. This certification enhances the company’s reputation as a global leader in proteomics and protein-based testing services, supporting its strategic growth and enabling the offering of new specialist pathology tests. The certification is expected to open new revenue streams and solidify the company’s position as an innovator in precision diagnostics, particularly in areas like diabetic kidney disease, esophageal cancer, and endometriosis.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced its Annual General Meeting (AGM) will be held on November 21, 2025, at the Harry Perkins Institute. The deadline for director nominations is October 3, 2025. Details of the AGM agenda and resolutions will be shared in the Notice of Meeting, with a video recording available to shareholders post-event. This announcement is part of the company’s ongoing commitment to transparency and shareholder engagement.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced a planned transition in its Board and Management, with Managing Director Dr. Richard Lipscombe set to retire in February 2026, marking his 25th anniversary with the company. The transition aims to strengthen the company’s leadership as it continues to commercialize its world-class technology in precision diagnostics and precision medicine. A specialist biotechnology executive search firm has been appointed to find a new CEO with global experience in diagnostics, medical technology, and digital health commercialisation. Dr. Lipscombe will remain in his role until a successor is appointed, ensuring a smooth transition.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd announced that their PromarkerEso blood test has shown high accuracy in diagnosing early stages of esophageal adenocarcinoma (EAC), a common form of esophageal cancer often caused by chronic acid reflux. This advancement could significantly improve early detection rates, offering a less invasive alternative to current diagnostic methods and potentially enhancing survival rates for patients, as EAC is often diagnosed too late for effective treatment.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has released its annual report for 2025, highlighting its focus on diseases such as esophageal cancer, oxidative stress, endometriosis, and diabetic kidney disease. The company’s mission is to enhance disease treatment through early detection and innovative solutions, which could significantly impact its operations and industry positioning by potentially offering new diagnostic tools and treatments for these conditions.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has released its Corporate Governance Statement and Appendix 4G in compliance with ASX Listing Rules. This announcement, authorized by the company’s Board of Directors, underscores the company’s adherence to corporate governance standards, which is crucial for maintaining investor confidence and ensuring transparency in its operations.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has released its preliminary final report for the financial year ending June 30, 2025. The company reported a revenue increase of 8% from ordinary activities compared to the previous year, reaching $960,389. However, the company also experienced a 27% increase in losses after tax, totaling $8,114,797. The report indicates a decrease in total revenue, including grants and other income, by 2% from the previous year. The company has announced that no dividends will be distributed for this period, and the Annual General Meeting is scheduled for November 21, 2025.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has successfully completed a $12 million capital raise to accelerate the launch of its diagnostic tests, including the Promarker®D test for diabetic kidney disease, which has been launched in the USA and Australia. The company is also advancing other diagnostic tests such as Promarker®Eso for esophageal cancer and Promarker®Endo for endometriosis, with significant progress in clinical validation and market readiness. The strategic expansion of its precision diagnostics capability, supported by a $6 million funding boost, positions the company to capitalize on the growing telehealth market and potential partnerships in the diagnostics sector.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
Proteomics International Laboratories Ltd has announced the publication of results for its next-generation PromarkerD test system in The Journal of Applied Laboratory Medicine. The test, which predicts diabetes-related chronic kidney disease (DKD) up to four years before symptoms appear, demonstrated excellent predictive performance and accuracy, outperforming current standard tests. This advancement is expected to significantly impact diabetes management by enabling earlier intervention and reducing healthcare costs, with the test now available in Australia and the USA for Type-2 diabetes patients.
The most recent analyst rating on (AU:PIQ) stock is a Hold with a A$0.43 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.